Insulet Corporation (PODD) is a leading medical technology company in Acton, Massachusetts, specializing in insulin delivery solutions for diabetes. With a market cap of $20.5 billion, it offers the tubeless Omnipod® Insulin Management System for continuous insulin delivery.

PODD is a large-cap stock valued at over $10 billion, underscoring its influence in the medical devices sector, particularly for those with Type 1 and insulin-dependent Type 2 diabetes. Despite a recent 17% dip from its 52-week high, it remains a key player in the global diabetes care market.

Shares of Insulet have declined 11.2% in the past three months, underperforming the Nasdaq Composite. However, in the long term, PODD has gained 11.1% over the past year, but lags behind the Nasdaq Composite’s performance.

Insulet’s Q3 earnings beat expectations, with a 29.9% revenue increase and a 37.8% rise in adjusted EPS. It raised its fiscal 2025 revenue growth guidance, boosting investor confidence. Despite trailing Medtronic plc, analysts are optimistic, giving PODD a “Strong Buy” rating.

PODD has been trading below its moving averages since late November, indicating a bearish trend. Despite recent underperformance, analysts forecast a 29.4% premium to its current price, with a mean price target of $381.

Read more at Yahoo Finance: Is Insulet Stock Underperforming the Nasdaq?